Literature DB >> 21391986

Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey.

J Jylhävä1, A Haarala, M Kähönen, T Lehtimäki, A Jula, L Moilanen, Y A Kesäniemi, M S Nieminen, M Hurme.   

Abstract

Pentraxin 3 (PTX3) is a novel candidate immunoinflammatory marker that has been reported to be associated with cardiometabolic risk factors and to predict adverse outcomes in individuals with cardiovascular disease (CVD). Despite being a member of the same pentraxin protein family as C-reactive protein (CRP), PTX3 probably reflects different aspects of CVD pathogenesis. In this study, we assessed plasma PTX3 correlates and determinants in the Health 2000 Survey population, which comprised n = 403 insulin-resistant subjects, n = 845 hypercholesterolaemic subjects and n = 311 hypertensive subjects, all aged between 46 and 76 years. In insulin-resistant subjects the PTX3 concentration was found to correlate directly with age, pulse pressure and indoleamine 2,3-dioxygenase (IDO) enzyme activity and inversely with total and low-density lipoprotein (LDL) cholesterol. In hypercholesterolaemic subjects, the PTX3 concentration correlated directly with HDL cholesterol, systolic blood pressure and pulse pressure, whereas in hypertensive subjects, the PTX3 concentration correlated directly with systolic blood pressure, pulse pressure and IDO activity. No correlation was observed between the concentrations of PTX3 and CRP, adiposity indicators or indicators of subclinical atherosclerosis in any of the subject groups. PTX3 concentration variations were attributed to variations in LDL cholesterol and IDO activity in insulin-resistant subjects and to pulse pressure in hypercholesterolaemic and hypertensive subjects. These results indicate that, in individuals at high risk of CVD, the PTX3 concentration is associated with cardiovascular risk factors but not with subclinical atherosclerosis.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21391986      PMCID: PMC3087913          DOI: 10.1111/j.1365-2249.2011.04354.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

2.  Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients.

Authors:  A Bosutti; G Grassi; M Zanetti; A Aleksova; M Zecchin; G Sinagra; G Biolo; G Guarnieri
Journal:  Clin Exp Med       Date:  2007-03       Impact factor: 3.984

3.  Home-measured blood pressure is more strongly associated with atherosclerosis than clinic blood pressure: the Finn-HOME Study.

Authors:  Teemu Niiranen; Antti Jula; Ilkka Kantola; Leena Moilanen; Mika Kähönen; Y Antero Kesäniemi; Markku S Nieminen; Antti Reunanen
Journal:  J Hypertens       Date:  2007-06       Impact factor: 4.844

Review 4.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

5.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

6.  Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.

Authors:  Roberto Latini; Aldo P Maggioni; Giuseppe Peri; Lucio Gonzini; Donata Lucci; Paolo Mocarelli; Luca Vago; Fabio Pasqualini; Stefano Signorini; Dario Soldateschi; Lorenzo Tarli; Carlo Schweiger; Claudio Fresco; Rossana Cecere; Gianni Tognoni; Alberto Mantovani
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

7.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina
Journal:  Eur Heart J       Date:  2007-08-28       Impact factor: 29.983

8.  Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction.

Authors:  Monica Salio; Stefano Chimenti; Noeleen De Angelis; Fabiola Molla; Virginia Maina; Manuela Nebuloni; Fabio Pasqualini; Roberto Latini; Cecilia Garlanda; Alberto Mantovani
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

9.  Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.

Authors:  Satoshi Suzuki; Yasuchika Takeishi; Takeshi Niizeki; Yo Koyama; Tatsuro Kitahara; Toshiki Sasaki; Mina Sagara; Isao Kubota
Journal:  Am Heart J       Date:  2007-09-27       Impact factor: 4.749

10.  The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps.

Authors:  Sébastien Jaillon; Giuseppe Peri; Yves Delneste; Isabelle Frémaux; Andrea Doni; Federica Moalli; Cecilia Garlanda; Luigina Romani; Hugues Gascan; Silvia Bellocchio; Silvia Bozza; Marco A Cassatella; Pascale Jeannin; Alberto Mantovani
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

View more
  11 in total

Review 1.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

2.  Association between smoking habits and severity of coronary stenosis as assessed by coronary computed tomography angiography.

Authors:  Masaya Yano; Shin-Ichiro Miura; Yuhei Shiga; Yuiko Miyase; Yasunori Suematsu; Kenji Norimatsu; Ayumi Nakamura; Sen Adachi; Hiroaki Nishikawa; Keijiro Saku
Journal:  Heart Vessels       Date:  2015-07-18       Impact factor: 2.037

3.  Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.

Authors:  N S Jenny; R S Blumenthal; R A Kronmal; J I Rotter; D S Siscovick; B M Psaty
Journal:  J Thromb Haemost       Date:  2014-06       Impact factor: 5.824

4.  Correlates of pentraxin 3 serum concentration in men and women with type 2 diabetes.

Authors:  Małgorzata Waluś-Miarka; Aleksandra Trojak; Przemysław Miarka; Maria Kapusta; Ewa Kawalec; Barbara Idzior-Waluś; Maciej T Małecki
Journal:  Innate Immun       Date:  2019-12-25       Impact factor: 2.680

5.  Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies.

Authors:  Michael Knoflach; Stefan Kiechl; Alberto Mantovani; Ivan Cuccovillo; Barbara Bottazzi; Qingbo Xu; Qingzhong Xiao; Arno Gasperi; Agnes Mayr; Marlene Kehrer; Johann Willeit; Georg Wick
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

6.  Association of Serum Pentraxin-3 and High-Sensitivity C-Reactive Protein with the Extent of Coronary Stenosis in Patients Undergoing Coronary Angiography.

Authors:  Vesna Vuković-Dejanović; Nataša Bogavac-Stanojević; Slavica Spasić; Vesna Spasojević-Kalimanovska; Dimitra Kalimanovska-Oštrić; Mirko Topalović; Zorana Jelić-Ivanović
Journal:  J Med Biochem       Date:  2015-09-19       Impact factor: 3.402

7.  Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia.

Authors:  Claudia Stefanutti; Fabio Mazza; Michael Steiner; Gerald F Watts; Joel De Nève; Daniela Pasqualetti; Juergen Paal
Journal:  Mediators Inflamm       Date:  2016-01-19       Impact factor: 4.711

8.  Obstructive Sleep Apnea, Hypertension, and Their Additive Effects on Atherosclerosis.

Authors:  Mario Francesco Damiani; Annapaola Zito; Pierluigi Carratù; Vito Antonio Falcone; Elioda Bega; Pietro Scicchitano; Marco Matteo Ciccone; Onofrio Resta
Journal:  Biochem Res Int       Date:  2015-12-01

Review 9.  The inflammatory protein Pentraxin 3 in cardiovascular disease.

Authors:  Francesco Fornai; Albino Carrizzo; Maurizio Forte; Mariateresa Ambrosio; Antonio Damato; Michela Ferrucci; Francesca Biagioni; Carla Busceti; Annibale A Puca; Carmine Vecchione
Journal:  Immun Ageing       Date:  2016-08-24       Impact factor: 6.400

10.  HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia.

Authors:  Michela Zanetti; Mariagrazia Zenti; Rocco Barazzoni; Federica Zardi; Annamaria Semolic; Michele Giuseppe Messa; Filippo Mearelli; Gianpaolo Russi; Maurizio Fonda; Luca Scarano; Enzo Bonora; Luigi Cattin
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.